ReviewMedicine and pharmacy reports2019
Multi gene panel testing for hereditary breast cancer - is it ready to be used?
Review in Medicine and pharmacy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.BMC cancer · 2024Pooled it
- Value of Conventional MRI, DCE-MRI, and DWI-MRI in the Discrimination of Metastatic from Non-Metastatic Lymph Nodes in Rectal Cancer: A Systematic Review and Meta-Analysis Study.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.Molecules (Basel, Switzerland) · 2022Pooled it
- Financing and health system capacity for precision medicine in Asia: a six country landscape analysis.Health affairs scholar · 2026Review
- Multigene panel testing reveals the spectrum of non-BRCA germline variants in BRCA1/2-negative breast, ovarian, and prostate cancer patients from a Turkish cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Advances in cancer genomics and precision oncology.Genes & genomics · 2025Review
- Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.Breast cancer research : BCR · 2025Article
- Clinically SignificantCancers · 2024Article
- Genome-wide DNA methylation profiles and breast cancer among World Trade Center survivors.Environmental epidemiology (Philadelphia, Pa.) · 2024Article
- Current status and perspectives of genetic testing in gastrointestinal cancer (Review).Oncology letters · 2024Review
- Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity.Oncotarget · 2023Article
- What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.Cancer medicine · 2023Article
- Prevalence of Pathogenic Germline Mutations in 13 Hereditary Cancer-Related Genes in Breast Cancer Patients in Narathiwat Province, Thailand.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer.Frontiers in genetics · 2023Article
- Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.Frontiers in genetics · 2023Review
- Screening of BRCA1/2 variants in Mauritanian breast cancer patients.BMC cancer · 2022Article
- Spectrum of germline pathogenic variants using a targeted next generation sequencing panel and genotype-phenotype correlations in patients with suspected hereditary breast cancer at an academic medical centre in Pakistan.Hereditary cancer in clinical practice · 2022Article
- Hereditary breast cancer and fertility preservation outcomes.Journal of assisted reproduction and genetics · 2022Article
- Global DNA Methylation Profiles in Peripheral Blood of WTC-Exposed Community Members with Breast Cancer.International journal of environmental research and public health · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common malignancies and the leading cause of death among women worldwide. About 20% of breast cancers are hereditary. Approximately 30% of the mutations have remained negative after testing
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.